Therapy-related myelodysplasia and fludarabine combination therapy – do the benefits justify the risk?

References

• Rai KR, Peterson BL, Appelbaum FR, et al Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000;343:1750–1757.
   PubMed Web of Science ®Google Scholar
• Niparuck P, Kanoksil W, Chuncharunee S, et al Therapy-related MDS/AML following fludarabine therapy for NHL and CLL in Thai patients. Leukemia and Lymphoma 2010; 51:2120–2125.
   PubMed Web of Science ®Google Scholar
• Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM, Kroll S. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol 2003;21:897–906.
   PubMed Web of Science ®Google Scholar
• Gill S, Carney D, Ritchie D, et al The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy. Ann Oncol 2010;21:331–334.
   PubMed Web of Science ®Google Scholar
• Vardiman JW, Arber DA, Brunning RD, et al Therapy-related myeloid neoplasms. In: Swerdlow SH, Campo E, Harris NL, et al, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. pp. 127–129.
   Google Scholar
• Morrison VA, Rai KR, Peterson BL, et al Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. J Clin Oncol 2002;20:3878–3884.
   PubMed Web of Science ®Google Scholar
• Tam CS, O'Brien S, Wierda W, et al Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008;112:975–980.
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Estey E, Glassman A, et al Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone [FND] plus rituximab and interferon alpha. Blood 2005;105:4573–4575.
   PubMed Web of Science ®Google Scholar
• Montoto S, Moreno C, Domingo-Domenech E, et al High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma. Haematologica 2008;93:207–214.
   PubMed Web of Science ®Google Scholar
• Bowcock SJ, Rassam SM, Lim Z, Ward SM, Ryali MM, Mufti GJ. High incidence of therapy-related myelodysplasia and acute leukaemia in general haematology clinic patients treated with fludarabine and cyclophosphamide for indolent lymphoproliferative disorders. Br J Haematol 2006;134:242–243.
   PubMed Web of Science ®Google Scholar
• Sandoval A, Consoli U, Plunkett W. Fludarabine-mediated inhibition of nucleotide excision repair induces apoptosis in quiescent human lymphocytes. Clin Cancer Res 1996;2:1731–1741.
   PubMed Web of Science ®Google Scholar
• Herbert KE, Morgan S, Prince HM, et al Stem cell factor and high-dose twice daily filgrastim is an effective strategy for peripheral blood stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine: results of a Phase II study with an historical comparator. Leukemia 2009;23:305–312.
   PubMed Web of Science ®Google Scholar
• Morgan SJ, Seymour JF, Grigg A, et al Predictive factors for successful stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine. Leukemia 2004;18:1034–1038.
   PubMed Web of Science ®Google Scholar
• Astrow AB. Fludarabine-related myeloid leukemia. J Clin Oncol 2003;21:3709; author reply, 10.
   PubMed Web of Science ®Google Scholar
• Lam CC, Ma ES, Kwong YL. Therapy-related acute myeloid leukemia after single-agent treatment with fludarabine for chronic lymphocytic leukemia. Am J Hematol 2005;79:288–290.
   PubMed Web of Science ®Google Scholar
• Sacchi S, Marcheselli L, Bari A, et al Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study. Haematologica 2008;93:398–404.
   PubMed Web of Science ®Google Scholar
• Hallek M, Fingerle-Rowson G, Fink A-M, et al Immunochemotherapy with fludarabine [F], cyclophosphamide [C], and rituximab [R] [FCR] versus fludarabine and cyclophosphamide [FC] improves response rates and progression-free survival [pfs] of previously untreated patients [pts] with advanced chronic lymphocytic leukemia [CLL]. Blood 2008;112:325.
   Web of Science ®Google Scholar
• Carney DA, Westerman DA, Tam CS, et al Treatment-related myelodysplasia and AML following fludarabine-combination chemotherapy. XIII International Workshop on Chronic Lymphocytic Leukemia Abstract book [Haematologica]. [Abstract]. 2009;94[s3]:s70.
   Google Scholar
• van de Loosdrecht AA, Alhan C, Bene MC, et al Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica. 2009;94:1124–1134.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223–232.
   PubMed Web of Science ®Google Scholar
• Mufti GJ, Gore SD, Santini V, et al Influence of karyotype on overall survival in patients with higher-risk myelodysplastic syndrome treated with azacitidine or a conventional care regimen. Blood 2009;114:1755.
   Web of Science ®Google Scholar
• Hershman D, Neugut AI, Jacobson JS, et al Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 2007;99:196–205.
   PubMed Web of Science ®Google Scholar